| pubmed-article:12173347 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12173347 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:12173347 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:12173347 | lifeskim:mentions | umls-concept:C1135161 | lld:lifeskim |
| pubmed-article:12173347 | lifeskim:mentions | umls-concept:C0332281 | lld:lifeskim |
| pubmed-article:12173347 | lifeskim:mentions | umls-concept:C1514475 | lld:lifeskim |
| pubmed-article:12173347 | lifeskim:mentions | umls-concept:C0237881 | lld:lifeskim |
| pubmed-article:12173347 | lifeskim:mentions | umls-concept:C0750502 | lld:lifeskim |
| pubmed-article:12173347 | pubmed:issue | 10 | lld:pubmed |
| pubmed-article:12173347 | pubmed:dateCreated | 2002-8-13 | lld:pubmed |
| pubmed-article:12173347 | pubmed:abstractText | With recent improvements in the treatment and outcome of patients with neuroblastoma (NB), the authors reassessed the prognostic importance of clinical and biologic markers in patients with Stage 4 NB who were treated at the Memorial Sloan-Kettering Cancer Center (MSKCC). | lld:pubmed |
| pubmed-article:12173347 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12173347 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12173347 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12173347 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:12173347 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12173347 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12173347 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12173347 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12173347 | pubmed:month | May | lld:pubmed |
| pubmed-article:12173347 | pubmed:issn | 0008-543X | lld:pubmed |
| pubmed-article:12173347 | pubmed:author | pubmed-author:QinJingJ | lld:pubmed |
| pubmed-article:12173347 | pubmed:author | pubmed-author:MoraJaumeJ | lld:pubmed |
| pubmed-article:12173347 | pubmed:author | pubmed-author:CheungNai-Kon... | lld:pubmed |
| pubmed-article:12173347 | pubmed:author | pubmed-author:GeraldWilliam... | lld:pubmed |
| pubmed-article:12173347 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12173347 | pubmed:day | 15 | lld:pubmed |
| pubmed-article:12173347 | pubmed:volume | 94 | lld:pubmed |
| pubmed-article:12173347 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12173347 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12173347 | pubmed:pagination | 2756-65 | lld:pubmed |
| pubmed-article:12173347 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:12173347 | pubmed:meshHeading | pubmed-meshheading:12173347... | lld:pubmed |
| pubmed-article:12173347 | pubmed:meshHeading | pubmed-meshheading:12173347... | lld:pubmed |
| pubmed-article:12173347 | pubmed:meshHeading | pubmed-meshheading:12173347... | lld:pubmed |
| pubmed-article:12173347 | pubmed:meshHeading | pubmed-meshheading:12173347... | lld:pubmed |
| pubmed-article:12173347 | pubmed:meshHeading | pubmed-meshheading:12173347... | lld:pubmed |
| pubmed-article:12173347 | pubmed:meshHeading | pubmed-meshheading:12173347... | lld:pubmed |
| pubmed-article:12173347 | pubmed:meshHeading | pubmed-meshheading:12173347... | lld:pubmed |
| pubmed-article:12173347 | pubmed:meshHeading | pubmed-meshheading:12173347... | lld:pubmed |
| pubmed-article:12173347 | pubmed:meshHeading | pubmed-meshheading:12173347... | lld:pubmed |
| pubmed-article:12173347 | pubmed:meshHeading | pubmed-meshheading:12173347... | lld:pubmed |
| pubmed-article:12173347 | pubmed:meshHeading | pubmed-meshheading:12173347... | lld:pubmed |
| pubmed-article:12173347 | pubmed:year | 2002 | lld:pubmed |
| pubmed-article:12173347 | pubmed:articleTitle | Evolving significance of prognostic markers associated with treatment improvement in patients with stage 4 neuroblastoma. | lld:pubmed |
| pubmed-article:12173347 | pubmed:affiliation | Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA. jmora@hsjdbcn.org | lld:pubmed |
| pubmed-article:12173347 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12173347 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:12173347 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12173347 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12173347 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12173347 | lld:pubmed |
